Omalizumab for the treatment of Chronic Inducible Urticaria in 80 patients.

Omalizumab for the treatment of Chronic Inducible Urticaria in 80 patients. Br J Dermatol. 2020 Jul 30;: Authors: Exposito-Serrano V, Curto Barredo L, Aguilera Peiro P, Gómez Armayones S, Serra-Baldrich E, Spertino J, Bonfill Ortí M, Figueras Nart I, Melé-Ninot G, Baliu-Piqué C, Sala Cunill A, Labrador M, Guilabert Vidal A, Fernández Chico N, Giménez-Arnau A Abstract Recruited were 80 participants with conditions as follows: solar urticaria (n=27), cold urticaria (n=22), symptomatic dermographism (n=11), cholinergic urticaria (n=10), delayed pressure urticaria (n=7), aquagenic urticaria (n=2), and heat urticaria (n=1). To compare the therapeutic benefits for different CindU subtypes, we evaluated response to omalizumab 300mg/4w using the Urticaria Control Test (UCT),1 grouping patients according to response: complete response (UCT=16); satisfactory response (UCT≥12-15); and non-response (UCT<12). We also analysed time to a satisfactory/complete response (fast ≤3 months and slow >4 months). We used omalizumab according to the EAACI/GA2 LEN/EDF/WAO guideline recommendations. PMID: 32730636 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research